Cambridge, UK, 25 May 2006 – BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, announces that its subsidiary BioProgress Technology Limited has filed a UK patent application for the use of its XGEL™ film system technology in a waste containment system to help prevent the spread of MRSA (Methicillin Resistant Staphylococcus Aureus) in hospitals.

The development of the containment system was assisted by the Company’s Advisory Board, which has also been involved with making recommendations for MRSA prevention systems for use across the NHS. The Company will explore whether there are additional areas in which the containment system or the XGEL™ film technology could be of use within the medical device sector.

The Company further announces that BioProgress Technology Limited has filed UK patent applications covering additional innovative developments to its TABWRAP™ encapsulation technology. The Company also continues to expand its patent families by filing applications in numerous international territories which claim priority from existing applications filed in the UK or through the Patent Cooperation Treaty route. At present, the BioProgress group owns 40 granted patents in 31 different patent families.

Richard Trevillion, CEO commented: “The Company continues to apply for patents to protect relevant commercial applications of its novel XGEL™ systems, whilst at the same time executing its growth as a speciality pharma and healthcare company. With respect to the MRSA prevention system, this is an endorsement of our market-led approach and illustrates how the non-ingestible containment side of our business can have real commercial advantages. We believe the system to be simple, not adding further complexity to the operating theatre, and helping to reduce the risk of infection. This IP filing is an example of how the Company’s core IP has applications in pharmaceutical and medical device markets.” 

For further information please contact: 

BioProgress plc	+44 (0)1223 394250
Richard Trevillion, Chief Executive Officer
Northbank Communications	+44 (0)207 886 8150
Sue Charles Gemma Bradley Justine Lamond

About BioProgress plc:

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London’s AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™  

Forward-Looking Information. 

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934.  To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may vary materially from the expectations contained in the forward-looking statements.  The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation.  Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company’s filings with the Securities and Exchange Commission.  The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.  This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice.  The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law.  Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. 

-ENDS-